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Abstract
Introduction: Decentralized HIV care for adults does not appear to compromise clinical outcomes. HIV care for children poses
additional clinical and social complexities. We conducted a prospective cohort study to investigate clinical outcomes in
children aged 6–15 years who registered for HIV care at seven primary healthcare clinics (PHCs) in Harare, Zimbabwe.
Methods: Participants were recruited between January 2013 and December 2014 and followed for 18 months. Rates of and
reasons for mortality, hospitalization and unscheduled PHC attendances were ascertained. Cox proportional modelling was
used to determine the hazard of death, unscheduled attendances and hospitalization.
Results: We recruited 385 participants, median age 11 years (IQR: 9–13) and 52% were female. The median CD4 count was
375 cells/mm3 (IQR: 215–599) and 77% commenced ART over the study period, with 64% of those who had viral load
measured achieving an HIV viral load <400 copies/ml. At 18 months, 4% of those who started ART vs. 24% of those who
remained ART-naïve were lost-to-follow-up (p < 0.001). Hospitalization and mortality rates were low (8.14/100 person-years
(pyrs) and 2.86/100 pyrs, respectively). There was a high rate of unscheduled PHC attendances (34.94/100 pyrs), but only 7%
resulted in hospitalization. Respiratory disease was the major cause of hospitalization, unscheduled attendances and death.
CD4 count <350cells/mm3 was a risk factor for hospitalization (aHR 3.6 (95%CI 1.6–8.2)).
Conclusions: Despite only 64% of participants achieving virological suppression, clinical outcomes were good and high rates
of retention in care were observed. This demonstrates that in an era moving towards differentiated care in addition to
implementation of universal treatment, decentralized HIV care for children is achievable. Interventions to improve adherence
in this age-group are urgently needed.
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Introduction
By 2015, an estimated 1.8 million children under 15 years
of age were living with HIV globally, the majority in Sub-
Saharan Africa, yet just half were accessing antiretroviral
therapy (ART) [1]. While the number accessing HIV treat-
ment represents gains from 2010, children lag disproportio-
nately behind adults in terms of ART coverage (49% of all
children infected were accessing ART in 2015 as compared
to just 21% in 2010) [1].
As ART programmes have scaled up, the major barriers to
ART access have been the lack of healthcare professionals
to provide HIV care, overcrowding of clinics and distance to
facilities where such care is available [2–6]. Among adults,
the increase in numbers of individuals accessing ART has
led to decentralization of HIV care provision from second-
ary to primary health care facilities, and task-sharing to
involve nurses in treatment of HIV infection [7,8]. The
aims of decentralization and task-sharing was to improve
access to care for patients and relieve pressure on heavily
overburdened secondary care facilities [9]. More recently,
differentiated care initiatives are focusing on providing ser-
vices which are more client focused and tailored to specific
needs of diverse populations of people living with HIV [10].
Zimbabwe has incorporated the concept of differentiated
care into its recent HIV treatment framework [11].
Clinical outcomes among adults HIV care in decentralized
programmes with nurse-led care have been comparable to
those in secondary healthcare facilities [7,8,12,13]. Provision
of HIV care to children and adolescents is associated with
additional complexities, which may impact on clinical out-
comes [9]. These include reliance on guardians, who are
often not biological parents, for access to and retention in
care, weight-based ART dosing, difficulties in discussing HIV
and disclosing HIV status to children [14–16]. Older children
and adolescents with HIV have higher rates of virological fail-
ure and attrition than adults [17,18]. These have led to a
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relative reluctance by primary care level providers to provide
HIV care to this age-group [19]. WHO guidelines now recom-
mend “treat all” living with HIV and Zimbabwe, since 2016,
has adapted its national guidelines to reflect this. Limited data
are available on ART care provision to children by nurses in
primary health care facilities [20]. We present clinical out-
comes among children and adolescents accessing decentra-
lized HIV care services provided by nurses in Harare,
Zimbabwe.
Methods
Study setting
A prospective cohort study of children aged 6–15 years was
conducted in seven primary healthcare clinics (PHCs) in south
west Harare, Zimbabwe between January 2013 and December
2014. Opt-out HIV testing and decentralized, nurse-led HIV
care for children was introduced at the seven PHCs with
supervision from by a physician. Children found to be HIV
positive were offered enrolment into the cohort which was
then followed over 18 months’ duration. Clinics where the
study was performed were treating adults with HIV infection
on a nurse-led basis as per Zimbabwe national guidelines but
had not been treating children living with HIV. Children were
followed up by research nurses for 18 months from time of
study enrolment. On completion of study follow up, HIV care
and management was transferred to clinic nursing staff.
Nurses in the employ of the clinic were trained on HIV care
and management for children over the duration of the study.
Although treatment and carewas provided by research nurses
with a physician backup, national guidelines for treatment and
management of children living with HIV were used. Staff
within the primary health care clinics where our study was
performed, who similar to the model used in the study, have
physician support weekly and were trained on management
of paediatric HIV treatment in tandem with research nurses.
Details of the study which includes baseline clinical data at
time of enrolment have been described elsewhere [21].
Research nurses based at each clinic were trained on paedia-
tric HIV testing and counselling and provision of HIV care,
treatment monitoring and management of infections, based
on the Integrated Management of Childhood Illness (IMCI)
algorithm, over a 2-week period prior to study commence-
ment [22]. TheMinistry of Health and Child Care training tools
were utilized and simple ART-dosing charts (available on
request) were produced to facilitate weight-based dosing.
Criteria for referral to secondary level facilities were pre-
defined, including “danger signs” based on the IMCI algo-
rithm. Nurses carried out ART eligibility screening, initiated
ART and provided follow-up care, supported by weekly visits
from a physician. Adherence counselling was provided by
primary care counsellors trained in paediatric HIV care. Each
visit to a PHC incurs a USD1 fee which is standard throughout
Zimbabwe. Cotrimoxazole and ART are provided free of
charge through the National ART Programme.
Participants
Children aged between 6 and 15 years who tested HIV
positive through provider-initiated HV testing and
counselling were enrolled into the cohort study (of whom
a proportion were simultaneously enrolled into a rando-
mized controlled trial to assess impact of household sup-
port to children living with HIV[trial registry number
PACTR201212000442288]), if they chose to access HIV
care at the clinic where they were diagnosed and gave
consent [23].
Study procedures
At the initial assessment visit within a week of HIV diag-
nosis, socio-demographic data, past clinical history and
current symptoms were assessed, and a standardized
examination performed. Participants underwent WHO
Staging and a CD4 count, using Alere Pima™ CD4 machine,
was measured [24]. All participants underwent counselling
and were started on cotrimoxazole. Participants who
screened positive on the WHO TB screen had sputum
examined onsite by Ziehl–Neelsen smear microscopy and
Xpert TB™ [25]. Participants were seen within 2 weeks of
the initial visit to assess adherence and determine side
effects of cotrimoxazole, and to commence ART if eligible.
The schedule for follow up was based on national guide-
lines, with visits at 2 and 6 weeks post ART commencement
and then on a 3-monthly basis. Participants not eligible for
ART at baseline underwent a 3-monthly symptom-based
review and examination to reassess ART eligibility. At each
visit, a standard proforma was used to collect information
on current symptoms, side effects of ART, history of contact
with primary healthcare and hospitalization since the pre-
vious visit (confirmed by patient-held records) and history
of incident infections.
Until February 2014, participants were ART eligible if CD4
was below 350 cells/mm3 or they had evidence of WHO
Stage 3 or 4 infections. ART regimens consisted of stavu-
dine/lamivudine and nevirapine for children under 12 years
or tenofovir/lamivudine and nevirapine if over 12 years of
age. Efavirenz was substituted for nevirapine in case of
concomitant TB treatment or nevirapine allergy. From
March 2014, Zimbabwe adopted the WHO 2013 consoli-
dated guidelines with the threshold for ART initiation
revised to 500 cells/mm3 and ART regimes were standar-
dized to zidovudine/lamivudine and nevirapine for those
under 12 years and not requiring TB treatment, and teno-
fovir/lamivudine and efavirenz for those over 12 years of
age [26]. CD4 count was performed 6 monthly for all
participants. HIV viral load testing was performed at
48 weeks post ART commencement using COBAS
Ampliprep/Taqman 48 Version 2.0.
Unscheduled visits were defined as visits occurring out-
side the scheduled visits for either a medical or non-med-
ical reason (e.g. counselling). Side effects were graded
according to the DAIDS grading system [27].Hospitalization
was defined as a participant spending one night or more in
a hospital. If a participant had more than one hospitaliza-
tion, they were counted separately even if related to the
same clinical issue. Transfer out was defined as a caregiver
informing the clinic of the participant changing care to
another clinic and a transfer letter being provided.
Participants who failed to attend more than two scheduled
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appointments were traced through a phone call and/or a
home visit. Participants were defined as having moved
away if they had moved care to another clinic without
informing clinic staff. Participants were deemed lost to
follow-up (LTFU) if they could not be traced. Tracing was
performed at clinic level by research nurses who phoned
the participant’s guardian on 2 occasions if a participant
had not returned for a visit within 3 months of the sched-
uled date. If after the second phone call a participant could
not be reached then a voluntary lay health worker visited
the house. If a participant died, the cause of death was
determined through hospital records. In the case of death
occurring outside of hospital, this was confirmed through
verbal autopsy with the caregiver.
Data management and analysis
Data was extracted from paper forms using optical mark
recognition software (Cardiff TELEFORM Intelligent
Character, Version 10.7) and analysed using STATA, version
12.1 (STATA Corporation, USA). Stunting and wasting were
defined as a height-for-age z-score and a weight-for-age
z-score of <-2, respectively [28]. Rates of hospitalization,
unscheduled visits and death were calculated. Cox propor-
tional modelling was used to determine the hazard of
death, unscheduled visits and hospitalization, controlling
for factors found to be significantly associated with the
outcome in univariate analysis.
Ethical considerations
Written informed consent was obtained from all caregivers
and written assent obtained from participants. Ethical
approval for the study was obtained from the Medical
Research Council of Zimbabwe, the Harare City Health
Department Ethics Committee, the Biomedical Research
and Training Institute Institutional Review Board and the
London School of Hygiene and Tropical Medicine Ethics
Committee.
Results
A total of 385 participants were enrolled into the study and
provided 450 person-years of follow up and a median of
504 days (IQR 1–515). The median age at HIV diagnosis was
11 years (IQR 9–13) and 52% were female. Most partici-
pants were infected with HIV through mother-to-child
transmission, and 59% were single or double orphans
(Table 1). The median CD4 count at HIV diagnosis was
375 cells/mm3 (IQR 215–599). Over the 18-month period,
296 (77%) participants commenced ART, 70% of whom did
so within 4 weeks of enrolment (Table 1). Of the 89 parti-
cipants who did not initiate ART, 7 were eligible according
to national guidelines and 82 were not eligible during
follow-up.
At the end of 18 months, 286 (74%) were still in care, 50
(13%) had transferred to another clinic, 12 (3%) moved to
another clinic without informing clinic staff, 9(2%) moved
away and did not transfer to another clinic, 13 (3%) died, 1
withdrew from the study after initial assessment and 14
(4%) were LTFU (Table 2). Importantly, those who did not
start ART were significantly more likely to be LTFU than
those who started ART (p < 0.001). CD4 counts for those
who commenced ART increased over the follow-up period,
with those who did not start ART (n = 89) maintaining their
CD4 counts (Figure 1). Of those who commenced ART
within 24 weeks of enrolment into the study (n = 273),
200 had a viral load sample collected between 40 and
72 weeks post ART, with 195 results obtained. 124 (64%)
of those whose viral load result was obtained had a viral
load <400 copies/ml.
Unscheduled visits
There were 146 unscheduled visits made by 99 participants
over the follow-up period, equivalent to a rate of 34.94/100
person years (95% CI 29.70–41.09). Ten unscheduled visits
resulted in hospitalization, all of whom were receiving ART.
The most common reason for an unscheduled attendance
to the clinic was illness (n = 133, 91%). Other reasons
included medication collection (n = 5, 3%) and additional
adherence counselling (n = 8, 6%). The major cause of
illness leading to an unscheduled visit was respiratory
tract infection (responsible for 45% of unscheduled visits
due to illness), followed by skin infections which accounted
for 22% of unscheduled visits due to illness (Table 3).
Side effects from ART resulted in unscheduled visits in 20
patients (15% of unscheduled visits due to illness). Of these,
Grade 1 nevirapine hypersensitivity was the most common
Table 1. Baseline characteristics of enrolled participants at
baseline (n = 385)
Characteristic N
Age (years), median (IQR) 11 (9,10,11,12,13)
Female 199 (52%)
Median (IQR), CD4 cells/mm3 375 (215–599)
CD4< 350 cells/mm3 177 (46%)
CD4 350–500 cells/mm3 74 (19%)
CD4> 500 cells/mm3 131 (34%)
WHO Stage 3 or 4
Mode of HIV acquisition 155 (40%)
Mother-to-child 369 (96%)
Horizontal 13 (3%)
Unknown 3 (1%)
Orphanhood 157 (41%)
Both parents alive 77 (20%)
Maternal Orphan/Father Alive 71 (18%)
Paternal Orphan/Mother Alive 58 (15%)
Double Orphan 22 (6%)
Unknown status of either parent
Biological parent as the current caregiver 220 (57%)
Started ART within 4 weeks of enrolment 206 (54%)
Started on ART over 18-month follow up 296 (77%)
Median days on ART for those who initiated
(IQR)
485 (359–495)
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side-effect (n = 8). Only one participant was hospitalized due
to ART side effects-for rehydration secondary to grade 3
vomiting. Other ART side effects reported at routine 3-
monthly follow up were uncommon and self-limiting-consist-
ing of nausea (6%), vomiting (6%), abdominal pain (3%),
diarrhoea (6%), fatigue (5%), rash (3%), jaundice (0.1%), dizzi-
ness (3%) vivid dreams (2%), and confusion (1%). Overall, side
effects of ART resulted in drug switches in 11 cases (n = 9 due
to nevirapine hypersensitivity, n = 1 anaemia due to zidovu-
dine and n = 1 grade 3 efavirenz hypersensitivity reaction).
Such switches were managed in the primary care clinics by
nursing staff with consultation from study physician.
Hospitalizations
There were 34 hospitalizations in 27 participants, 9 of
which resulted in death. The rate of the hospitalization
was 8.14/100 person years (95% CI 5.81–11.39). Lower
respiratory tract disease was commonest reason for admis-
sion (Table 4). TB was the cause of hospitalization in 8
participants diagnosed through sputum testing using
geneXpert or based on chest X-ray findings. Six participants
were hospitalized more than once for the same clinical
diagnosis (1 admitted twice for HIV-related anaemia, 1
admitted twice for lower respiratory tract infection, 1
admitted twice for Steven Johnson’s syndrome secondary
to cotrimoxazole due to ongoing symptoms, and 1 admitted
thrice for recurrent lower respiratory tract infection). Two
participants were admitted twice but for different clinical
events. Only three hospitalizations occurred in participants
not taking ART, two of which were due to malaria. Only one
was HIV related, namely HIV-associated anaemia and
thrombocytopenia, and resulted in death. The CD4 count
at hospitalization in this participant was 1114 cells/mm3.
Deaths
The mortality rate was 2.86/100 pyrs (95% CI 1.65–4.95). Of
the 13 deaths in the cohort, 12 occurred in hospital and
respiratory disease was the most common cause (Table 5).
Table 2. Outcomes at 18 months of cohort participants by ART initiation status
Total
N = 385
Initiated ART over follow
up period N = 296
Did not initiate ART over
follow up period N = 89
p-
value
In care to end of study follow up 286 (74.3%) 243 (82.1%) 43 (48.3%) <0.01
Planned transferred to another clinic 50 (13.0%) 30 (10.1%) 20 (22.5%) <0.01
aLeft area without transfer of care 9 (2.3%) 2 (0.7%) 7 (7.9%) <0.01
aNot in care and untraceable 14 (3.6%) 6 (2.0%) 8 (9.0%) <0.01
No planned transfer, but was found
in care at another clinic
12 (3.1%) 3 (1.0) 9 (10.1) <0.01
Withdrew from study 1 (0.3%) 0 (0.0%) 1 (1%) 0.06
Died 13 (3.4%) 12 (4.1%) 1 (1%) 0.18
aascertained through phone calls and home visits.
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Figure 1. Median CD4 count over 18 month follow up by ART status.
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The median CD4 count at enrolment of those who died was
73 cells/mm3 (IQR 12–205) and 77% of those who died had
WHO Stage 3 or 4 disease at enrolment. The median time
from enrolment to death was 76 days (IQR 59–410).
A CD4 count less than 350 cells/mm3 at enrolment,
WHO stage 3 or 4 HIV disease and wasting were asso-
ciated with hospitalization and death on univariate analy-
sis (Table 6). CD4 count less than 350cells/mm3 and
advanced WHO stage remained significantly associated
with the outcome in multivariate analysis for hazard of
hospitalization (aHR 3.6 (95%CI 1.6–8.2), aHR 2.6 (95% CI
1.1–6.2)), no variables remained significantly associated
with the hazard of death. Being older (HR 2.1 (95%CI
1.4–3.1), WHO stage 3 or 4 disease (HR 1.5 (95% CI 1.0–
2.1) and wasting (HR 1.8 (95% CI 1.3–2.7)) were associated
with having unscheduled visits due to illness. On multi-
variate analysis, association with being in an older age
group (aHR 1.9 (95%CI 1.3–3.1)) and wasting (aHR 1.8
(95%C.I 1.0–2.3)) remained significant.
Discussion
Our study demonstrated that nurse-led HIV care for children
and adolescents is possible in primary care settings. The rate
of retention in care was comparable to that reported in
facility-based settings and higher than a recent retrospective
cohort review of children attending decentralized care in
Swaziland [20,29]. Provision of HIV care in primary care
facilities reduces the distance that patients need to travel
to access treatment, and this may help improve retention in
care [3,20]. Notably, the rate of retention in care was sig-
nificantly lower in those who did not start ART, with half of
those who did not initiate ART being LTFU. This finding has
been reported previously and may be because patients per-
ceive no benefit in attending for care if they are not
Table 3. Reasons for unscheduled visits due to illness
(n = 133)
Cause of unscheduled attendance N (%)
Respiratory tract infection 60 (45%)
Upper respiratory tract infection 27
Lower respiratory tract infection 16
Pulmonary TB 11
Otitis Media 2
Tonsillitis 4
Skin infections 29 (22%)
Oro-labial Herpes Simplex 5
Herpes Zoster 5
Chicken Pox 1
Bacterial skin infection 15
Fungal skin infection (Tinea capitis or corporis) 2
Papular pruritic eruption 1
Gastrointestinal disease 16 (12%)
Gastroenteritis 9
Chronic diarrhoea 2
Hepatitis A 1
Oral candidiasis 3
Oesophageal candidiasis 1
Antiretroviral therapy side effects 20 (15%)
Grade 1 Nevirapine hypersensitivity 8
Grade 2/3 NNRTI skin hypersensitivity 8
Grade 2/3 vomiting 3
Anaemia 1
Miscellaneous 8 (6%)
Minor trauma 1
Gingivitis 2
Conjunctivitis 2
Mumps 1
TB lymphadenitis 2
Table 4. Causes of hospitalization (n = 34)
Cause of hospitalization N (%)
Respiratory Illness n = 18 (53%)
Pulmonary TB 7
Disseminated TB 1
Lower respiratory tract infection 9
Pneumocystis jiroveci pneumonia 1
Neurological Illness n = 5 (15%)
Bacterial meningitis 1
Cryptococcal meningitis 2
CNS lymphoma 1
Seizure (cause unknown) 1
Miscellaneous n = 11 (32%)
Hyperglycaemia 1
Anaemiaa 3
Congestive Cardiac Failure 1
Gastroenteritis 1
Vomiting Secondary to ART 1
Malariab 2
Stevens–Johnson syndrome secondary to
cotrimoxazole
2
Numbers refer to hospitalization events rather than numbers of
participants admitted,
a
n = 1 not on ART,
b
n = 2 not on ART
Table 5. Causes of death amongst cohort participants over
18 month follow up (n = 13)
Cause of death n (%)
Pulmonary TB 4 (31)
Lower respiratory tract infection 4 (31)
Malignancy – CNS lymphoma 1 (7)
Congestive cardiac failure 1 (7)
Meningitis 1 (7)
Accidental drowning 1 (7)
Anaemia/Thrombocytopenia 1 (7)
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Table 6. Cox proportional hazard ratio for hospitalization, unscheduled visit due to illness and death
Hospitalization
N = 34
Unscheduled visit
N = 118
Death
N = 13
Total N Rate (95% CI)
Crude hazard
ratio AHR
a
N Rate (95% CI)
Crude hazard
ratio AHR
a
N Rate (95% CI)
Crude hazard
ratio AHR
a
Age 11–15 200 17 7.7 (4.8–12.5) 0.9 (0.5–1.8) - 82 37.3 (30.1–46.4) 2.1 (1.4–3.1) 1.9 (1.3–2.9) 7 3.0 (1.4–6.2) 1.1 (0.4–3.3) -
6–10 185 17 8.6 (5.3–13.8) 1 36 18.2 (13.1–25.2) 1 6 2.8 (1.2–6.1) 1
Sex Female 199 15 6.9 (4.2–11.5) 0.7 (0.4–1.4) - 68 31.4 (24.7–39.8) 1.3 (0.9–1.8) - 9 3.8 (2.0–7.4) 1.6 (0.5–5.5) -
Male 186 19 9.44 (6.0–14.8) 1 50 24.9 (18.8–32.8) 1 4 1.8 (0.68–4.9) 1
CD4 at
enrolment b
<350 177 26 13.1 (8.9–19.3) 4.1 (1.8–9.4) 3.6 (1.6–8.3) 65 32.8 (25.7–41.8) 1.4 (0.9–1.9) - 11 5.2 (2.9–9.3) 5.0 (1.1–23.1) 4.2 (0.9–19.8)
>350 205 7 3.2 (1.5–6.8) 1 53 24.5 (18.7–32.0) 1 2 0.8 (0.2–3.4) 1
WHO stage 3–4 155 25 14.8 (10.0–21.9) 4.0 (1.9–8.6) 2.6 (1.1–6.2) 59 34.9 (27.1–45.1) 1.5 (1.0–2.1) 1.2 (0.8–1.9) 10 5.4 (2.9–10.0) 4.1 (1.1–15.2) 2.5 (0.6–10.7)
1–2 230 9 3.6 (1.9–6.9) 1 59 23.7 (18.4–30.6) 1 3 1.1 (0.3–3.5) 1
ART within
4 weeks
Y 206 22 9.2 (6.1–14.0) 1.4 (0.7–2.9) - 69 28.9 (22.8–36.5) 1.1 (0.75–1.6) - 10 3.9 (2.1–7.3) 2.1 (0.6–7.9) -
N 179 12 6.7 (3.8–11.8) 1 49 27.3 (20.0–36.6) 1 3 1.5 (0.5–4.7) 1
Stunting Y 91 13 13.0 (7.5–22.4) 1.9 (1.0–3.8) - 31 31.0 (21.8–44.1) 1.1 (0.74–1.7) - 4 3.7 (1.4–9.9) 1.8 (0.45–6.0) -
N 294 21 6.6 (4.3–10.1) 1 87 27.4 (22.2–33.8) 1 9 2.6 (1.4–5.0) 1
Wasting Y 105 19 17.3 (11.1–27.2) 3.5 (1.8–6.8) 2.1 (1.0–4.5) 47 42.9 (32.2–57.1) 1.8 (1.3–2.7) 1.5 (1.0–2.3) 7 5.9 (2.8–12.4) 4.7 (1.4–16.2) 2.7 (0.7–10.6)
N 280 15 4.9 (2.9–8.1) 1 71 23.0 (18.3–29.1) 6 1.8 (0.8–4.0) 1
aAdjusted for factors significantly associated with the outcome in univariate analysis; AHR: adjusted hazard ratio; b data missing for n = 3
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receiving treatment [30,31]. The 2015 WHO guidelines
recommend initiation of ART regardless of disease stage or
age and this may facilitate retention in care [32].
Worryingly, only two-thirds of children achieved virologi-
cal suppression after starting ART, similar to the proportion
reported in a recent study in a clinic in a central hospital in
Harare [33]. Other studies have demonstrated virological
suppression rates ranging from 27 to 89% in adolescents
[34]. Notably, 172 (44.7%) of our study cohort received
community lay worker support due to participation in a
randomized controlled trial which may have potentially
increased the proportion of participants with viral load
suppression. There were no drug-stock outs over the dura-
tion of our study and so the virological unsuppressed rate
most likely reflects suboptimal adherence. Since study com-
pletion, viral load testing has become available at primary
care clinics within Zimbabwe’s health service. Children are
expected to take ART for at least two decades longer than
adults and the need for interventions in this age-group to
support sustained adherence to minimize emergence of
drug resistance cannot be over-emphasized, particularly in
resource-limited settings where options for second and
third-line ART are limited.
Despite a good immunological response to treatment, a
high frequency of PHC attendances occurred outside sched-
uled clinic appointments. Most unscheduled presentations
were, however, due to minor illness and were managed at
primary care level, with only a minority resulting in referral
to hospital for further management. Such referrals were
decided on due to the nature of the limited services pri-
mary care health facilities are able to provide in the event
of more serious illness. Decentralized HIV care therefore
provides a system for triage and reduces the burden on
secondary health facilities, making it a sustainable system
for chronic care provision.
The leading cause of unscheduled visits, hospitalization
and death was respiratory tract infections, even among
patients on ART. We have previously reported a high bur-
den of chronic lung disease in perinatally infected children
and adolescents, which is associated with considerable
morbidity including recurrent respiratory tract infections,
poor lung function and reduced exercise tolerance [35].
The recurrent respiratory tract infections observed in this
study may be due to underlying chronic lung disease. The
pathogenesis is poorly understood but is thought to be a
sequela of chronic infections and/or HIV-mediated chronic
inflammation. Once established chronic lung disease
appears to be poorly responsive to ART, and children with
recurrent respiratory tract infections may require further
interventions such as additional prophylactic antibiotics or
anti-inflammatory agents [36].
Notably, 8 hospitalizations were TB related, 4 of them
resulting in death, despite active case finding at baseline
through sputum testing and at follow up through WHO
symptom screening. This demonstrates the low sensitivity
of the WHO TB screening tool, and reflects the paucibacil-
lary nature of TB in children. TB preventative therapy using
isoniazid prophylaxis had not been widely implemented in
Zimbabwe at commencement of the study and no
participant received it over the study period. Skin disease
was the second most common cause of unscheduled visits
to PHCs. Recurrent skin infections are strongly associated
with HIV infection in children, and in high HIV prevalence
settings should prompt HIV testing [37,38]. Side effects of
ART accounted for only 15% of unscheduled attendances.
Importantly, most patients with side effects were managed
in primary care necessitating few drug switches, all effected
at primary care level.
As has been reported in other studies, advanced disease
stage and immunosuppression were risk factors for both
hospitalization and death [39,40]. The median CD4 count at
diagnosis was 375 cells/mm3, and the median age at diag-
nosis in a cohort where nearly all participants were infected
perinatally was 11 years, implying an average delay of a
decade in diagnosing HIV infection. Given the high HIV-
associated mortality observed in infants, there is limited
awareness that a third of HIV-infected infants survive to
adolescence even without treatment [41]. Therefore, HIV
testing is only offered when children present with condi-
tions indicative of HIV infection, by which time they have
often developed advanced disease [19,29]. However, at
least a quarter of children retained high CD4 counts (>500
cells/mm3) and remained ineligible for ART based on cur-
rent national guidelines. While a sub-group of these may be
true long-term non-progressors or elite controllers, many
remain pauci-symptomatic and may not prompt healthcare
workers to offer HIV testing [33,34].
Older age was associated with more frequent unscheduled
visits but not death and hospitalization. This might reflect a
combination of survival bias and longer life-time exposure of
uncontrolled viremia. While these children survived into ado-
lescence without major illness, the uncontrolled viremia may
have resulted in a higher prevalence and more prominent
chronic disease phenotype such as chronic lung disease.
The strengths of the study were the prospective design and
that participants were actively followed up to ascertain out-
comes. Detailed clinical data were collected to establish the
reasons for visits to health facilities and cause of death. The
study was conducted in public sector services and therefore
the findings are broadly generalizable. Limitations include the
lack of viral load data in all participants (73% of those eligible
had viral load measured). There is a risk that the Cox propor-
tional hazard models for death and admission may be over-
fitted due to a small number of events. To mitigate this risk, no
variables were specified a priori. Diagnoses such as respiratory
tract infections were made in PHC were based on symptoms
and clinical examination, as diagnostic facilities are limited.
Conclusions
Our study shows that decentralized nurse-led HIV care for
children is possible and results in clinical outcomes compar-
able to those reported in children elsewhere in southern
Africa [20]. Implementation of 2015 WHO guidelines that
recommend universal treatment of all HIV-infected indivi-
duals, is likely to result in a substantial increase in children
eligible for treatment, particularly given the current low ART
coverage. Considerable investment in age-appropriate HIV
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testing strategies, training and support for primary health
care providers and interventions to support adherence need
to be strengthened to achieve universal access and optimum
treatment outcomes among children and adolescents.
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